Genomcore at ESHG 2026: from the lab to the clinical decision
What the sector debated at ESHG and why data infrastructure is the conversation that matters.
The European Human Genetics Conference is the sector's leading annual gathering in Europe. It brings together the continent's scientific and clinical community to debate the state and future of genomics: variant classification, long-read sequencing, pharmacogenomics, large language models applied to clinical data, and the ethical and regulatory frameworks reshaping the field.
For Genomcore, ESHG is not just another conference. Genomics is where the company started, and it remains the core of what we build: the infrastructure that takes genomic data out of the laboratory and turns it into real clinical decisions.
What we observed on the ground
This year's edition confirmed a trend we have been tracking in the field for some time: the sector's conversation has matured. The question is no longer whether AI can help in genomics. The question is how, with what guarantees, and on what data foundation.
The most relevant discussions were not centered on variant analysis, but on what comes before and after: data structuring, storage, computation and governance. Institutions such as Genomics England, UK Biobank and major Spanish public health systems — CatSalut, SERMAS, SERIS, the Valencia Community — were present in force, representing that reality: scale demands infrastructure, not just analytical tools.
Pharmacogenomics and large-scale language models applied to clinical data attracted considerable scientific interest. On the clinical side, reference figures such as Encarna Guillén and leading centers including the Carlo Besta Institute and Hospital La Paz underlined the need for data management systems capable of matching real clinical complexity.
What Genomcore BIMS delivers where the sector needs it
BIMS, Genomcore's platform, addresses precisely that problem. It integrates genomic, clinical, imaging and device data into a single structured model, without requiring custom engineering. It is designed for real-world health systems, not laboratory environments.
Genomcore's presence at ESHG is not a visibility exercise. It is the most direct way to test what we build against what the sector needs. And what the sector consistently needs is digital infrastructure that goes beyond analysis.
Genomcore participates in ESHG to listen, to learn, and to identify the institutions and teams with whom it makes most sense to move forward together.
